Thérapeutique
21 oct 2011
Quels risques à l’arrêt du natalizumab ?
C. Papeix - P525 « Natalizumab discontinuation in clinical practice : a systematic observational study from the national TYSEDMUS cohort of multiple sclerosis patients treated with natalizumab in France »